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Abstract  
Amine transaminases offer an environmentally sustainable synthesis route for the production of 
pure chiral amines.  However, their catalytic efficiency towards bulky ketone substrates is 
greatly limited by steric hindrance and therefore presents a great challenge for industrial 
synthetic applications. Hereby we report an example of rational transaminase enzyme design to 
help alleviate these challenges. Starting from the Vibrio fluvialis amine transaminase that has no 
detectable catalytic activity towards the bulky aromatic ketone 2-acetylbiphenyl, we employed a 
rational design strategy combining in silico and in vitro studies to engineer the transaminase 
enzyme with a minimal number of mutations, achieving an high catalytic activity and high 
enantioselectivity. We found that by introducing two mutations W57G/R415A detectable 
enzyme activity was achieved. The rationally designed best variant, 
W57F/R88H/V153S/K163F/I259M/R415A/V422A, showed an improvement in reaction rate 
by > 1716-fold towards the bulky ketone under study, producing the corresponding enantiomeric 
pure (S)-amine (ee value of > 99%).  
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Introduction 
 
There is a high demand in the pharmaceutical and agrochemical industry for efficient 
synthesis of enantiomerically pure chiral amines, which are important building blocks for the 
preparation of pharmaceuticals and agrochemicals. As of 2006 90% of the FDA approved drugs 
were chiral compounds1. Amine transaminases (TAms) offer a green synthesis route for the 
production of pure chiral amines2. TAms catalyse (in many instances with great 
stereoselectivity) the transfer of an amino group from a primary amine compound to a ketone 
compound and vice-versa, using pyridoxal phosphate (PLP) as cofactor. The generally accepted 
catalytic mechanism of TAms consists of two half reactions in a ping-pong bi–bi mechanism 
(Fig. 1a)3. In the first half reaction, an internal aldimine that is formed between a PLP bound to 
the enzyme (E: PLP) and a catalytic lysine reacts with the amino donor, yielding an external 
aldimine. A neutral lysine residue is released which then catalyzes internal hydrogen 
rearrangement via a planar quinonoid intermediate, yielding a ketimine. In the second half 
reaction, the ketimine is hydrolyzed, releasing the product ketone and yielding a pyridoxamine 
5’-phosphate (PMP) bound to the enzyme (E: PMP). Then a ketimine complex is formed 
between the E: PMP and the substrate ketone, which finally regenerates the E: PLP via a second 
planar quinonoid intermediate and external aldimine, yielding the secondary chiral amine 
product. 
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Figure 1.  (a) General mechanism of the TAm-catalyzed transamination reaction where a ketone 
is converted to the corresponding amine. The upper panel shows the first half reaction and the 
lower panel shows the second half reaction. The intermediates investigated in this study were the 
E:PMP:substrate complex, the enzyme:planar quinonoid and the succeeding enzyme:external 
aldimine. (b). Asymmetric synthesis of (1S)-1-(1,1'-biphenyl-2-yl)ethanamine (amine 2). The 
transamination reaction under study is between the substrate 2-acetylbiphenyl (ketone 1) and the 
amine donor Isopropylamine and catalyzed by V. fluvialis TAm.  
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The catalytic site of these enzymes can accommodate ketones as well as amines, and can be 
divided into large and small binding pockets (Fig. S1)4. The large binding pocket has a dual 
recognition capacity accommodating not only the bulky substituents of amines and ketones but 
also the carboxyl group of amino acids, pyruvate, etc. 4a. The small binding pocket adjacent to 
PLP accommodates small substituents and tends to repel the carbonyl group of substrates4a. 
Notwithstanding the intrinsic promiscuous nature of these enzymes their catalytic efficiency 
towards large ketone substrates is greatly limited by the steric hindrance 4b. Therefore, it is 
necessary to expand the scope of these enzymes to accommodate bulkier substrates.  
Some significant advances in the engineering of TAms have been achieved recently. One of 
the most relevant studies was the engineering of the (R)-selective-TAm from Arthrobacter sp. to 
produce sitagliptin starting from prositagliptin ketone5.  The initial modelling-aided site-saturated 
mutagenesis protocol allowed the design of a mutated enzyme that provides a modest 0.7% 
conversion of prositagliptin ketone.  Starting from this mutant, an impressive improvement in 
catalysis was achieved by numerous rounds of direct evolution that culminated in an enzyme 
with 89% conversion. However, 27 amino acids had to be mutated in this process.  
The (S)-selective-TAms were also engineered to catalyse ketones larger than the native 
amine-acceptor pyruvate (Fig. S2) 6. Midelfort et al. obtained a rationally engineered Vibrio 
fluvialis TAm_F19W/W57F/F85A/R88K/V153A/K163F/I259V/R415F and improved the 
catalytic conversion of  (R)-ethyl 5-methyl 3-oxooctanoate by 60-fold following an in silico and 
saturation mutagenesis protocol6a; Park et al. improved the amination of 2-oxo-octanoate by 4-
fold with a Paracoccus denitrificans  mutant TAm_V153A by following an alanine-scanning 
mutagenesis protocol that involved mutating six active site residues in the small binding pocket 
(L56, V153, F19, B:F85, L56, Y150 and L417)6b. Han et al. studied in detail the transformation 
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of some non-native ketones catalyzed by TAm from Ochrobactrum anthropi following an 
alanine-scanning mutagenesis protocol where the small-pocket-forming residues Y20, L57, W58, 
V154, F86, Y151 and B:T324 were mutated 6c,6d. They improved the reaction rate of this TAm 
towards butyrophenone by 110-fold with mutant L57A6d and improved the kcat/KM towards 
acetophenone by 340-fold with mutant W58L6c.  Moreover, advances have also been made for 
the conversion of relevant amines into ketones and aldehydes by mutating V. fluvialis TAm. 
Nobili et al. increased the conversion of (S)-1-phenylbutylamine to the corresponding ketone by 
30-fold with TAm_F85L/V153A6e, Genz et al. got a ~3-fold improvement in the conversion of 
the same amine to pentanal by mutating W57 and R4156f, Cho et al. got a ~41-fold improvement 
in the conversion of 4-phenylbutylamine by mutating W576g.    
However, when compared with the aforementioned (R)-selective TAm case5, the 
improvement in the catalytic efficiency of (S)-selective TAms is moderate and the ketone 
substrates are not significantly bulkier than the native substrates. Further efforts are necessary to 
obtain an efficient (S)-selective-TAm that can convert bulky ketone substrates, producing pure 
chiral amine compounds.   
In this study, we rationally engineered the (S)-selective TAm from V. fluvialis to catalyse 2-
acetylbiphenyl (ketone 1) to the corresponding amine (amine 2), using isopropylamine which has 
been suggested to be an ideal amino donor for asymmetric amination of ketones (Fig. 1b.). The 
wild type (WT) enzyme showed no detectable catalysis towards the bulky ketone 1 while the 
best variant with only seven mutations converted 42 % of 1g/L of the substrate yielding the 
corresponding (S)-amine product with an enantiomeric excess (ee) value of > 99% (Table1). This 
corresponds to an improvement in the reaction rate by > 1716-fold (Table 1).  
 7 
The rational design in this study is based on an iterative strategy that combines state-of-the-
art in silico with in vitro methodologies to engineer TAm as new biocatalysts.  The high 
conversion efficiency associated with the engineered enzyme adds an excellent example in the 
existing scarce successes in expanding the substrate scope of the enzymes to obtain pure chiral 
amine products. This strategy substantially decreases the screening effort requested by traditional 
directed evolution methods based on error-prone polymerase chain reaction, DNA shuffling and 
saturation mutagenesis, and provides a new approach in reshaping the binding pocket of the 
enzymes to catalyze industrially impeded reactions.  
 
Methods 
The designed V. fluvialis_TAm variants resulted from an iterative rational strategy that 
involves exhaustive structural analysis, molecular docking, MD simulations, Quantum 
Mechanics calculations, in silico protein structural stability study, co-evolution network analysis 
and in vitro screening. In total, 113 mutants were rationally designed and assessed in vitro.  
Computational methods 
The substrate ketone 1 (Fig. 1, S2) was docked into the WT V. fluvialis TAm (PDB code: 
4E3Q)6a and to the rationally designed mutants. The enzyme was modelled in presence of the 
PMP cofactor intermediate (Fig. S7a). All systems were subsequently submitted to molecular 
dynamics simulations (RMSD, the root mean square deviation of the alpha-carbon atoms can be 
seen in Fig. S11). To assess the enantioselectivity of the selected V. fluvialis variants we docked 
to them the planar quinonoid. For the best variant we additionally analysed the pro-(S) external 
aldimine intermediate.  Both the planar quinonoid and the pro-(S) external aldimine structures of 
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the best variant were submitted to molecular dynamics simulations (RMSD of the alpha-carbon 
atoms can be seen in Fig. S12 and Fig. S13).  
Parameterization of the substrate  
     The geometries of the substrate ketone 1 and its corresponding planar quinonoid and pro-(S) 
external aldimine intermediates were initially optimized in Gaussian 097 using Density 
Functional Theory (DFT) method with the exchange-correlation functional B3LYP and the 6-
31g(d) basis set8, following a procedure employed in the previous literature 9. The effect of 
solvent was approximately considered using the Polarizable Continuum Model (PCM)10, as 
implemented in Gaussian 09, with the dielectric constant of water being set to 80. Atomic point 
charges were then calculated by fitting the HF/6-31g(d) generated electrostatic potential to 
atomic point charges using the RESP algorithm11. These point charges were subsequently used in 
the docking calculations and MD simulations. 
Molecular docking  
Starting with the WT crystal structure, the models of the variants were built using the 
mutation tool and side chain rotamer search algorithm of the Swiss pdb viewer software12. 
Molecular docking was performed using the AutoDock 4.2 suite with the Lamarckian genetic 
algorithm (LGA) and the standard free energy scoring function 13. A grid box was centred on the 
amino group of the PMP cofactor. The catalytic lysine was deprotonated. A total of 100 LGA 
runs were carried out for each ligand:protein complex.  The population was 300, the maximum 
number of generations was 27,000 and the maximum number of energy evaluations was 
2,500,000. For each system analysed the top ranked structure corresponds to lowest binding 
energy structure of the most populated cluster with the lowest mean binding energy.   
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Molecular dynamics  
Molecular dynamics (MD) simulations were performed for the WT enzyme and the variants 
using the Amber molecular dynamics program (AMBER14)14 with the parm99SB15 and GAFF16 
force fields. The structures were placed within a truncated octahedral box (spacing distance of 10 
Å) of TIP3P waters and counter ions were added to neutralize the system. The systems were first 
subjected to two energy minimizations using the steepest descent and conjugate gradient 
algorithms and were subsequently slowly heated to 300 K during 50 ps with small restraints of 
10 kcal/mol/Å (to all atoms except waters and ions) in a NVT ensemble using Langevin 
dynamics. For each system under study, three 10-ns production simulations with random initial 
velocities were carried out at 300 K in the NPT ensemble using Langevin dynamics with a 
collision frequency of 1.0 ps–1. Constant pressure periodic boundary conditions were imposed 
with an average pressure of 1 atm. Isotropic position scaling was used to maintain pressure with 
a relaxation time of 2 ps. The time step was set to 2 fs. SHAKE constraints were applied to all 
bonds involving hydrogen atoms17. The particle mesh Ewald (PME) method was used to 
calculate electrostatic interactions with a cut-off distance of 10 Å18.  
Co-evolution network  
     The co-evolution network of PLP-dependent aminotransferase superfamily - Ornithin-
transaminase like family (~30,000 sequences) was calculated using Comulator software 19,20.  
Standard parameters were used.   
Prediction of binding energy 
We used the Zone Equilibration of Mutants (ZEMu) protocol to predict the change in binding 
free energy upon amino acid substitution (ΔΔG)21, as implemented in MMB22. In this protocol 
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first a flexibility zone is defined, which includes the residue to mutate plus two residues on each 
side.  The flexibility zone is treated in torsion space while the rest of protein is rigid. Then a 
physics zone is established. This includes all residues within 12Å of the flexibility zone, inside of 
which PARM99 electrostatic and van der Waals forces are active.  After equilibration of the 
flexibility zone the energy is evaluated with the KB potential FoldX23. The calculation is 
performed for both the WT ΔGwt and the mutant ΔGmut. An estimate of the experimental change 
in binding free energy, ΔΔGexp, is obtained by ΔGmut – ΔGwt. 
Experimental methods 
Chemicals 
The starting material ketone 1 (Fig. 1, S2a) was purchased from Fluorochem (Hadfield, UK) 
and the product standard (1S)-1-(2-Biphenylyl)ethanamine was purchased from AP Bioscience, 
LLC (Princeton, USA). 1-acetophenone was purchased from Sigma-Aldrich (Dorset, UK) and 
racemic α-methylbenzylamine was obtained from AlfaAesar (Heysham, UK). PLP was obtained 
from AlfaAesar (Heysham, UK), Isopropylamine hydrochloride from Tokyo Chemical Industry 
UK Ltd. (Oxford, UK) and mono and dibasic potassium phosphate from Sigma-Aldrich (Dorset, 
UK). Components of bacterial cultures were purchased from Sigma-Aldrich (Dorset, UK), VWR 
Chemicals (Lutterworth, UK), kanamycin from ForMedium (Hunstanton, UK) and 
Isopropylthiogalactosid (IPTG) from Carbosynth (Compton, UK). 
Gene synthesis and cloning  
The genes for the V. fluvialis TAm WT and mutant variants designed in this work were 
commercially synthesized by GenScript (Piscataway, USA). All TAm genes were cloned into the 
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pET28a(+) vector using EcoRI and XhoI restriction sites and transformed into E. coli 
BL21(DE3) cells (Thermo Fisher Scientific).   
Transaminase screening 
Transformed E. coli BL21(DE3) clones carrying TAm variant plasmids were transferred into 
the wells of 96-deep well plates containing 500 µL of LB medium (10 g/L NaCl, 10 g/L 
tryptone, 5 g/L yeast extract) supplemented with 50 µg/mL kanamycin. Plates were sealed with 
breathable heat seals and incubated at 37 °C and 1400 rpm in a plate incubator (MB100-4A, 
Hangzhou Allsheng Instruments Co.,Ltd, China) overnight. For protein expression, 10 µL 
preculture was transferred into 490 µL fresh LB medium supplemented with 50 µg/mL 
kanamycin in new 96-deep well plates. The plates were sealed with breathable heat seals and 
incubated for 2-3 hours followed by addition of IPTG to a final concentration of 1 mM. Plates 
were resealed with breathable seals and further incubated at 25 °C and 1400 rpm. Subsequently 
the cells were pelleted by centrifugation at 4500 rpm (Rotina 420, Hettich), the supernatant 
discarded and the plate with the cell pellets frozen at -20 °C.  
For TAm activity screenings, plates were thawed and 180 µL phosphate buffer (pH 8) 
containing 0.56 mM PLP and 0.56 M Isopropylamine hydrochloride were added to the cell pellet 
of each well. Following addition of 20 µL 51 mM ketone 1 plates were sealed with aluminium 
foil heat seals and incubated at 40 °C and 1500 rpm in a plate incubator for 18 hours. Reactions 
were stopped by addition of 800 µL 62.5 % acetonitrile, followed by resealing of the reaction 
plates and mixing at 1500 rpm in the plate incubator. Subsequently, reactions were centrifuged 
for 15 min at 4500 rpm (Rotina 420, Hettich) and supernatants analysed by HPLC. 
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Preparation of TAm cell-free extract 
1 L of LB medium (10 g/L NaCl, 10 g/L tryptone, 5 g/L yeast extract) supplemented with 50 
µg/mL kanamycin was inoculated with 10 mL of an overnight culture and incubated at 37 °C  
and 180 rpm (Forma orbital shaker model 491, Thermo Scientific) until an optical density (OD) 
of 0.6 was reached. Subsequently, protein expression was induced by addition of IPTG to a final 
concentration of 1 mM followed by an overnight incubation at 25 °C. After incubation, cells 
were harvested by centrifugation at 4 °C and 6000 rpm (Sorvall RC 6 plus, Thermo Scientific), 
resuspended in 0.1 M potassium phosphate containing 0.25mM PLP and sonicated for 8 cycles 
of 10 seconds and cooled on ice. Following centrifugation at 6000 rpm (Sorvall RC 6 plus, 
Thermo Scientific) at 4 °C supernatants were freeze-dried and the obtained cell free extract 
powder stored at 4 °C. 
Purification of WT TAm and its variants 
For protein purification wild-type TAm and the four variants describe in Table 1 were expressed 
in E. coli BL21 (DE3). Cells bearing plasmid pET28a-TAm were cultured at 37 °C in 1 L of LB 
medium containing 50 μg/mL kanamycin to mid-log phase (A600nm ∼ 0.6). Before protein 
induction, with 1 mM IPTG, LB medium was allowed to cool down to 25°C and after induction 
further incubated at 25°C, 200 rpm for 18 hours. The induced culture was centrifuged at 5000 rpm 
at 4 °C for 10 min, suspended in 20 mL of buffer A consisting of 50 mM sodium phosphate buffer, 
pH 7.4, containing 0.3 M NaCl and 20 mM imidazole to which protease inhibitor cocktail 
(cOmplete Mini, EDTA-free, Roche Diagnostics GmbH, Germany) was added to a final 1x 
concentration. The cells were lysed on ice using sonication (Soniprep 150, MSE Ltd., UK) at 16 
µm amplitude for 9 cycles (10 seconds pulse and 10 seconds pause) for 3 min and centrifuged at 
12000 rpm for 30 min. The supernatant was filtered through a 0.22 µm syringe filter unit (Millex-
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GP, Merck Millipore Ltd., Ireland) and loaded onto a 2 mL HisPur Cobalt Resin (Thermo 
Scientific, IL USA) column, pre-equilibrated with 5 column volumes of buffer A. The column was 
washed (1.7 mL/min) with 50 column volumes of buffer A before TAm was eluted (0.7 mL/min) 
with 2 column volumes of buffer A containing 0.25 M imidazole and protease inhibitor cocktail. 
Imidazole was removed, and the protein was concentrated to 0.5 mL by centrifugation, washing 
three times with 1 mL of buffer A containing no imidazole, with a centrifugal filter with 3000 
MWCO membrane (Amicon Ultracel 3K, Millipore Ltd., Ireland). Glycerol was added to 10% 
(v/v), and the purified protein was distributed in 50 μL aliquots, flash-frozen in liquid nitrogen and 
stored at    -80 °C until use. Protein concentrations were determined by micro BCA protein assay 
kit (Thermo Scientific, IL USA) using BSA as a standard. 
Transaminase assay 
Unless otherwise specified, TAm enzyme reactions were prepared in 96-deep well plates by 
mixing 100 µL 20 mg/mL cell free TAm extract in phosphate buffer (pH 8) with 80 µL 
phosphate buffer (pH 8) containing 2.5 mM PLP and 2.5 M Isopropylamine hydrochloride, 
followed by addition of 20 µL 51 mM ketone 1. Plates were sealed with aluminium foil heat 
seals and incubated at 40 °C and 1500 rpm in a plate incubator (MB100-4A, Hangzhou Allsheng 
Instruments Co., Ltd, China) for 18 hours.  
Reactions were stopped by addition of 800 µL 62.5 % acetonitrile, followed by resealing of 
the reaction plates and mixing at 1500 rpm in the plate incubator. Subsequently, reactions were 
centrifuged for 15 min at 4500 rpm (Rotina 420, Hettich) and supernatants analysed by HPLC. 
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Determination of kinetic parameters 
Apparent kinetic parameters of the purified enzymes were obtained under pseudo-one-
substrate conditions. Initial rate measurements were performed with varying concentrations of 
substrates (0.2–200 mM for acetophenone, 0.025–25 mM for ketone 1), while keeping 
concentration of amine donor (IPA) constant at 1M. HPLC analysis was used to monitor the 
progress of the reactions. The kinetic parameters (KM and kcat) were estimated by non-linear 
regression of the initial reaction rates using GraphPad Prism 6 (GraphPad Software, Inc., USA). 
HPLC Analysis 
Ketone 1 
Sample analysis was performed using an Agilent 1290 U-HPLC system equipped with a 
Kinetix C18 column (2.1x50mm, 100A, 1.7µm, Phenomenex, Macclesfield, UK) heated to 40 °C 
using 0.1 % phosphoric acid as mobile phase A and MeCN (190 far UV grade, Romil, 
Waterbeach, UK) supplemented with 0.1 % phosphoric acid as mobile phase B. Sample volumes 
of 1-10 µL were injected and analysed in the following gradient run: 10 % mobile phase B to 
95 % mobile phase B in 1.0 min followed by 0.5 min at 95 % mobile phase B and 0.5 min at 
10 % mobile phase B at a flow rate of 0.5 mL/min. Conversion of ketone 1 was observed at 
210 nm. 
For chiral analysis, the Agilent 1290 U-HPLC system was used with an Amylose 2 column 
(4.6x150mm, 1.7µm, Phenomenex, Macclesfield, UK) heated to 45 °C. Sample volumes of 10 
µL were injected and analysed in a 15 min isocratic run of 65% 0.1% ammonium hydroxide / 
35 % MeCN at a flow rate of 1 mL/min. Formation of amine product enantiomers was observed 
at 210 nm. 
Acetophenone 
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Sample analysis was performed using an Agilent 1290 U-HPLC system equipped with a 
Kinetex C18 column (3×100 mm, 100 Å, 2.6 µm, Phenomenex, Macclesfield, UK) heated to 40 
°C using 0.1 % phosphoric acid as mobile phase A and MeCN (190 far UV grade, Romil, 
Waterbeach, UK) supplemented with 0.1 % phosphoric acid as mobile phase B. Sample volumes 
of 1–10 µL were injected and analysed in the following gradient run: 5 % mobile phase B to 
95 % mobile phase B in 3.0 min followed by 1 min at 95 % mobile phase B and 1.2 min at 5 % 
mobile phase B at a flow rate of 0.5 mL/min. Conversion of acetophenone was observed at 
210 nm. 
 
Racemic 1-(2-Biphenylyl)ethanamine standard synthesis 
A mixture of 60 mg ketone 1, 116 mg ammonium formate and 60 mg zinc in 0.7 ml ethanol 
was heated to reflux under argon overnight. A further 3 equivalents of zinc and 6 equivalents of 
ammonium formate were added and heated under reflux continued overnight. The reaction 
mixture was filtered through celite and washed with ethanol. The filtrate was concentrated on 
rotary evaporator at 40°C to leave a whitish oil followed by addition of 10 mL 1M HCl and 
washing with diethyl ether (2x 20 mL). The aqueous layer was basified to pH 10 with 
ammonium hydroxide and extracted with DCM (1x 10, 2x 5 mL). The organic layer was washed 
with 10 mL brine and dried over Na2SO4. Finally it was concentrated on rotary evaporator and 
12 mg clear oil obtained. 
Thermal stability 
The thermal stability of the WT and the variants described in table 1 was measured. The reactions 
were carried out with 5 mM ketone 1, 1M IPA, 0.01 mM enzyme, 0.1 M K·phosphate buffer (pH 
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8.0), 10% DMSO (v/v). Enzymes in phosphate buffer were pre-incubated in 96-well plates at 40°C, 
50°C and 60°C for 18 h. Reactions with the pre-incubated enzyme were set up next day in parallel 
with control reactions. Reactions were carried out at the same temperature that was used for pre-
incubation. After 4 h reactions were quenched with 62.5% acetonitrile and analysed with HPLC. 
All reactions were performed in triplicates. 
 
Results and Discussion 
 
There has been so far limited success in the engineering of (S)-selective TAm enzymes to 
catalyse significantly large ketone substrates6a-d, when compared with the improvements 
obtained for a (R)-selective TAm enzyme 5. Here we studied the conversion of ketone 1 by the 
homodimeric V. fluvialis TAm (Fig. 1b, S2). It is worth noting that ketone 1 is larger than the 
substrates studied in the previous research (Fig. S2) 6a-d. A substrate (R)-ethyl 5-methyl 3-
oxooctanoate (Fig. S2b) has a similar molecular weight, however, it is less bulky than ketone 1.  
In addition, until completion of this present work, WT V. fluvialis TAm has shown no detectable 
catalysis towards ketone 1 (Table 1), while all other studies started with measurable activities 
with the respective WT Tams. The design of the initial V. fluvialis TAm variants resulted from 
an exhaustive structural analysis, molecular docking and molecular dynamics simulations. After 
initial simulations for the WT V. fluvialis TAm, we observed that the substrate ketone 1 is 
essentially held in place by a π-stacking interaction with the side chain of F19 and a strong 
hydrogen bond with the indole side chain of the residue W57 (Fig. 2).  However, this seems to be 
a non-catalytic pose because the distance between the amino group of PMP and the ketone 1 
carbonyl is large (5.1 Å) and the phenyl group of ketone 1 is turned to PMP.  Thus the PMP 
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nucleophilic attack to the ketone 1 carbonyl carbon seems highly improbable since the 
approximation of the substrate to PMP would involve a considerable steric clash (Fig. 2). 
 
 
 
Table 1.  Transamination of ketone 1 by the V. fluvialis TAm and engineered variants.   
 WT W57G/R415A W57G/K163F/R415A 
W57G/I259M/
R415A 
W57F/R88H/
V153S/K163F/
I259M/R415A
/V422A 
ee (%) (S)-amine ND >99 >99 >99 >99 
Conversion 
(Mean ± SD,%) a ND 2.49±0.11 5.63±0.64 1.9±0.13 42.14±0.89 
KM [mM] b NA 0.263 0.405 0.188 0.155 
kcat [s-1] b NA 7.88x10-4 3.29x10-3 1.19x10-3 6.68x10-3 
kcat/KM [M-1·s-1] NA 3.00 8.13 6.30 43.0 
Fold increase in 
kcat/KM c 
NA 1 3 2 14 
Reaction rate 
[μM/h] d 
ND 
e 14.3 36.2 14.4 171.6 
Reaction rate 
fold increase - >143 >362 >144 >1716 
a Reaction conditions: 5 mM substrate, 1M IPA, 0.01 mM of purified enzyme (Fig. S14), 0.1 M potassium phosphate buffer (pH 
8.0), 10% DMSO (v/v), 40°C, 18 h. All reactions were performed in triplicates. 
b Kinetic parameters are the apparent rate constants calculated from the initial reaction rates at a fixed concentration of amine 
donor (1M). 
c Fold change with W57G/R415A as reference 
d Reaction rates are initial reaction rates. Reaction conditions: 5 mM substrate, 1M IPA, 0.01 mM of purified enzyme, 0.1 M 
K·phosphate buffer (pH 8.0), 10% DMSO (v/v), 40°C. Reactions were performed in duplicates. 
e ND - not detectable. Reaction rate for WT was no more than 0.1 μM/h, considering the detection limit. 
 
As can be seen from the MD simulation of the WT TAm (Fig. 2), the bulky W57 is placed in the 
middle of the active centre and it does not provide a space large enough to accommodate the 
bulky substrate in a catalytic pose. Therefore, it is imperative to mutate W57 to smaller non-
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polar residue. In all our mutants this residue was mutated to alanine, glycine or phenylalanine, 
respectively (Table S1). Previous studies on ω-TAms indicated that the enzymes’ specificity 
highly depends on the binding step rather than the subsequent catalytic step24.  Thus, mutations 
introduced in the large binding pocket would not only open the pocket but also create strong 
intermolecular interactions with the substrate. Therefore, in addition to W57, we also focused our 
attention on other relevant binding pocket residues (K163, A228, E257, V258, I259, V422, 
R415) (Fig. S1, Table S1). On the other hand, the small binding pocket residues are positioned in 
the vicinity of the subunits interface. Thus, it could negatively alter the intrinsic stability of the 
enzyme if this pocket is excavated to fit a bulky substrate. Therefore we mutated only five 
residues of this pocket, namely G55, L56, H83, B: R88, V153 (Fig. S1, table S1), in order to 
enhance the intermolecular interactions in the subunit interface and therefore the enzyme overall 
structural stability. Due to the non-polar nature of the ketone substrate it is imperative to 
decrease the overall charge of active centre. Positions R88, K163 and R415 in V. ﬂuvialis TAm 
were mutated in the synthesis of imagabalin 6a. However, in the best variant reported, the residue 
at the position 88 was still mutated to a positively charged lysine residue. In the present study, 
we decreased the overall active site charge by mutating the positively charged residues R88, 
K163 and R415. Additionally, we also mutated residues that interact with PMP, L56 and B: R88 
(Table S1).  
In total 72 mutants were assessed experimentally in the first round of in vitro screening, from 
which several initially designed mutants were validated to have a detectable conversion of the 
substrate. Those involved positions 57, 88, 153, 163, 259, 415, 422 (Table S1), among which the 
most efficient double mutant is V. fluvialis TAm W57G/R415A (Table 1).  Subsequently, we 
designed multiple variants based on the screening results, structural analysis and the calculated 
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evolution correlation network. The first round screening results and structural analysis indicated 
that better activity could be achieved by combining V. fluvialis_TAm W57G/R415A with 
mutations at positions 88, 163, 259. The evolution correlation network of the active centre 
residues based on analysis of 30,000 homologous sequences disclosed obvious correlation 
between I259 and residues V153 and V422 (Fig. S3). This was also taken into account in the 
design of the new multiple mutants.   
 
Figure 2. MD reference structure of ketone 1 docked to WT V. fluvialis TAm in presence of 
PMP. The active centre residues are represented by sticks with the carbons of Chain A (green 
ribbon) coloured in grey and the carbons Chain B (cyan ribbon) coloured in cyan. Relevant 
distances are shown (Å). The MD reference structure corresponds to the 
structure with lowest RMSD (alpha-carbon atoms) in relation to the average structure of the 
simulation. No significant changes were observed in the MD replicas. 
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The designed multiple mutants were examined in silico using molecular docking and 
molecular dynamics simulations (the latter were based on the best docking results) and then 
assessed experimentally in a second round of in vitro screening (41 multiple mutants) (Table S1).  
 
Best mutants identified from rational design  
 
The best V. fluvialis TAm mutant identified from the first round in vitro screening was 
W57G/R415A (Fig. 3a).  Introduction of the W57G substitution enlarges the active centre pocket 
and adds extra flexibility to the loop where this residue is located.  As a result the phenyl group 
of ketone 1 is now far from PMP. It occupies the space vacated by the loss of the tryptophan 
residue and establishes London dispersion forces with the side chain of I259. The R415A 
substitution further opens the active centre pocket and decreases the positive charge (Fig. 3a) of 
the pocket, contributing to an increase in the affinity for the hydrophobic substrate. The distance 
between the ketone 1 carbon and the PMP amino nitrogen decreases to 3.7 Å, which is a much 
more reasonable distance for the nucleophilic attack than that observed in the WT enzyme.  This 
distance is also comparable with the reported distance of 2.65 Å for a PMP: acetophenone 
intermediate  along the reaction path of the  related Chromobacterium violaceum TAm, which  
was obtained from density functional theory calculations25. This double mutant provided an 
experimental conversion of 2.49% for ketone 1, that corresponds to an improvement in the 
reaction rate by > 143-fold (Table 1).  
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Figure 3.  MD reference structures of ketone 1 docked to V. fluvialis TAm mutants in presence 
of PMP. (a) TAm_W57G/R415A (b) TAm_W57G/K163F/R415A (c) 
TAm_W57G/I259M/R415A. The active centre residues are represented by sticks with the 
carbons of Chain A (green ribbon) coloured in grey and the carbons of Chain B (cyan ribbon) 
coloured in cyan. Relevant distances are shown (Å). The MD reference structure corresponds to 
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the structure with lowest RMSD (alpha-carbon atoms) in relation to the average structure of the 
simulation. No significant changes were observed in the MD replicas. 
 
Based on the promising catalytic activities exhibited in the first round in vitro screening, new 
mutants of V. fluvialis TAm were designed and tested in a second round in vitro screening (Table 
S1).   Here we describe in detail two of the best triple mutants as well as the overall best multiple 
mutant identified from the second round screening.  One of those is the variant TAm 
_W57G/K163F/R415A.  It should be noticed that a phenylalanine at position 163 is rarely 
observed in the analysed homologous sequences (Fig. S4). Only ~0.4% of those sequences have 
a phenylalanine and the most common residues are the polar glutamine and asparagine residues 
as well as the charged lysine (Fig. S4). However, due to the non-polar nature of ketone 1 it was 
imperative to decrease the overall charge of active centre.  To achieve this, a new variant was 
designed where the positively charged residues K163 and R415 were mutated into neutral 
residues. In this variant the hydrophobicity of the active centre is increased while the charged 
R415 and K163 residues were simultaneously mutated into non-polar residues alanine and 
phenylalanine, respectively (Fig. 3b). The substrate establishes a strong π-stacking interaction 
with Phe86 of chain B and is also involved in London dispersion forces with the side chains of 
residues L56, A415 and V422.  The distance between the ketone 1 carbon and the PMP amino 
nitrogen is 4.1 Å (Fig. 3b). In vitro analysis demonstrated that this mutant reached 5.63% 
conversion of ketone 1, which is an improvement in catalytic efficiency by 3-fold over the 
double mutant (Table 1). 
The second triple mutant V. fluvialis TAm W57G/R415A/I259M was designed to introduce a 
S/π interaction between the sulphur atom of the methionine residue 259 and the aromatic phenyl 
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group of ketone 1 (Fig. 3c). S/π interactions between the methionine sulphur and aromatic rings 
are stronger than hydrophobic interactions and known to play an important role in protein 
stabilization26.   In addition, the methionine is less prone to oxidation while forming a stable S/π 
interaction. Therefore, it is beneficial to introduce such interactions in the rational design of 
enzymes27.  Similar to the other triple mutant (Fig. 3b), we also observed a strong π-stacking 
interaction between ketone 1 and the side chain of Phe86 from chain B, as well as London 
dispersion forces between the substrate and the side chains of residues L56, A415 and V422 
(Fig. 3c). The distance between the carbonyl carbon atom of ketone 1 and the amino nitrogen 
atom of PMP is decreased to 3.6 Å. The catalytic efficiency improves by 2-fold over the double 
mutant (Table 1).  
Based on the initial in vitro screening results, the co-evolution network and molecular 
modelling, we also designed multiple variants with 4 to 7 substitutions (Table S1). Among them, 
one variant (Fig. 4) W57F/R88H/V153S/K163F/I259M/R415A/V422A exhibit significantly 
improved activity. The catalytic efficiency improves by 14-fold over the double mutant (Table 
1). It converts up to 42.14 % of ketone 1 at 1g/L of substrate (Table 1) and corresponds to an 
improvement of the reaction rate by > 1716-fold. This variant also shows an improvement in the 
reaction rates and kinetic parameters towards acetophenone, a standard TAM substrate (Table 
S2).  
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Figure 4.  MD reference structure of ketone 1 docked to V. fluvialis TAm W57F/R88H/ 
V153S/K163F/I259M/V422A/R415A in presence of PMP. The active centre residues are 
represented by sticks with the carbons of Chain A (green ribbon) colored in grey and the carbons 
of Chain B (cyan ribbon) colored in cyan. Relevant distances are shown (Å). The MD reference 
structure corresponds to the structure with lowest RMSD (alpha-carbon atoms) in relation to the 
average structure of the simulation. No significant changes were observed in the MD replicas. 
As previously mentioned, due to the non-polar nature of ketone 1 it was imperative to 
decrease the overall charge of active centre such that K163 and R415 were mutated into neutral 
residues.  To further reduce the charge, we introduced another mutation at B: R88H, which is 
located along the subunit interface and close to the active centre vicinity (Fig. 4). The position 57 
was mutated into phenylalanine such that the phenyl ring of W57F simultaneously interacts with 
both ketone 1 and the side chain of I259M via a strong T-shaped π-stacking and a S/π interaction, 
respectively (Fig. 4). In contrast, this interaction was not observed in W57G (Fig.S5). As a result 
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of these mutations, in the best variant, the substrate’s acetophenone core establishes T-shaped π-
stacking interactions with the side chains of both B:F86 and F19 while the latter in turn interacts 
with B:F85 through a T-shaped π-stacking. The side chains of V422A and R415A also interact 
directly with ketone 1 via hydrophobic interactions. This extremely well packed network of 
strong π-stacking interactions highly contributes to a stable arrangement of ketone 1 in the active 
centre pocket. The pose of ketone 1 is also catalytically preferable with the distance between the 
substrate carbonyl carbon and the PMP amino group approximately equal to 3.1 Å, being quite 
close to the distance of 2.65 Å reported for the PMP: acetophenone intermediate25.  
In the first round screening the position 153 nested at the subunit interface was mutated to the 
charged residues arginine and lysine as well as to serine and alanine (Table S1), Although the 
most commonly observed amino acids at this position are arginine and glutamate according to 
the homologous sequences studied (Fig. S4), the results of the screening and further structural 
analysis clearly indicated that adding a charged residue at this position was not beneficial to the 
activity. We therefore propose introducing of negative charge would negatively affect the overall 
hydrophobicity of the active centre, which is not ideal for our substrate.  Thus in the second 
round of screening only mutant V153S was considered. Mutating the valine residue 153 into 
serine can introduce additional interactions with chain B via an ion-dipole interaction with K126 
and a dipole-dipole interaction with H319 (Fig. S6). We calculated changes in binding free 
energy (ΔΔG) in the variant TAm_V153S using ZEMu21. The ΔΔGV153S obtained was -2.01 
kcal/mol, which indicates that V153S mutation may increase the subunit interface affinity, and 
hence the overall structural stability of the enzyme (Fig. S6).   
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Stability of the WT and engineered enzymes was examined in vitro. After 18h the best 
variant retains 98 % and 90% of activity at 40°C and 50°C, respectively, while the other variants 
suffer a significant decrease in activity at 50°C (Table S3, S4).   
 
Active centre polarity 
 
The active centre of the WT enzyme is positively charged (Fig.5a). Changing the polarity of 
the active site pocket was essential to better accommodate our non-polar substrate to increase its 
conversion (Fig. 5). In the mutant V. fluvialis TAm W57G/R415A, the charge of the active 
centre becomes less positive and more delocalized (Fig.5c). Substitution of the bulky 
hydrophobic W57 with glycine enlarges the active site pocket (Fig.5b) and the simultaneous 
substitution of the positively charged R415 with an alanine reduces its positive charge (Fig.5c). 
In the subsequent engineering of the enzyme, this double mutant is conjugated with the K163F 
mutation that further contributes to decrease in the positive charge of the active centre (Fig. 5e). 
In the best variant, V. fluvialis TAm W57F/R88H/V153S/K163F/I259M/R415A/V422A, the 
positive charges of residues R88, K163 and R415 are completely removed. Simultaneously the 
W57F, I259M and V422A mutations introduce a well-packed hydrophobic network, making the 
binding pocket more compact and the active centre substantially more neutrally charged (Fig.5f).  
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Figure 5.  The electrostatic potential (±5 kT/e) of the MD reference structures of the V. fluvialis 
TAm (ketone 1 was docked in the presence of PMP) plotted on the solvent-accessible surface of 
the detected cavities. The graphs (a)-(e) indicates a progression of colors from blue (positive) to 
red (negative) (a) WT TAm; (b) TAm_W57G; (c) TAm_W57G/R415A; (d) TAm_W57G/ 
I259M/R415A; (e) TAm_W57G/K163F/R415A; (f) TAm_W57F/R88H/V153S/K163F/I259M/ 
R415A/V422A.  
 
The combined effect of the favourable interactions and changes in active site polarity 
provides a valid explanation for the experimentally observed activity of the best variant (Table 
1).  
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Selectivity  
 
In the second half-reaction of the generally accepted mechanism for ω-TAm (Fig. 1), the 
amino acceptor and the PMP cofactor react leading to the formation of a ketimine intermediate. 
This is followed by proton abstraction and consequent electronic rearrangement of the ketimine 
intermediate, which is subsequently converted into a planar quinonoid intermediate. In the next 
step, the side chain of the catalytic lysine donates a proton to the nitrogen binding carbon of the 
planar quinonoid and an external aldimine intermediate is formed. It is at this point that the 
reaction specificity is determined. The half-reaction ends with the release of the product amine 
and the formation of a Schiff base (internal aldimine) between the aldehyde group of PLP and 
the side chain of the catalytic lysine. Thus, in order to assess the enantioselectivity of the mutants 
we focused on the study of the planar quinonoid and the pro-(S) external aldimine intermediates 
(Fig. S7b & c). The spatial arrangement of the catalytic lysine with respect to the planar 
quinonoid commands the orientation of the amino group of the catalytic lysine, which undergoes 
nucleophilic attack towards the nitrogen binding carbon of the quinonoid intermediate. This 
consequently dictates the chirality of the resulting external aldimine. We observed that the spatial 
arrangement of all the variants favours the formation of pro-(S) external aldimine and 
consequently the formation of the end S-amine product (Fig. 6, Fig. S8, S9). For the best variant 
TAm_W57F/R88H/V153S/K163F/I259M/R415A/V422A we also conducted a MD analysis of 
the pro-(S) external aldimine. Superimposing of the MD reference structures of the planar 
quinonoid intermediate and the pro-(S) external aldimine demonstrates that the intermediates 
share an identical active centre pose, which further indicates the (S)-chiral amine is the end 
product synthesized by the designed variant (Fig. S10).  
 29 
In the subsequent in vitro analysis, it was confirmed that all the described mutants produce 
the S-amine with an enantiomeric excess (ee) of > 99% (Table1). 
 
 
Figure 6.  MD reference structure of V. fluvialis TAm W57F/R88H/V153S/K163F/I259M/ 
V422A/R415A docked into the planar quinonoid. The active centre residues are represented by 
sticks with the carbons of Chain A (green ribbon) colored in grey and the carbons of Chain B 
(cyan ribbon) colored in cyan. Relevant distances are shown (Å). The MD reference structure 
corresponds to the structure with lowest RMSD (alpha-carbon atoms) in relation to the average 
structure of the simulation. No significant changes were observed in the MD replicas. 
 
Conclusions     
 We rational engineered the (S)-selective TAm from V. fluvialis to catalyze conversion of the 
bulky 2-acetylbiphenyl to the corresponding (S)-amine. To improve substrate binding and 
conversion we focused on enlarging the large binding pocket while increasing hydrophobicity at 
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positions W57, M259, V422 and R415, decreasing the charge of the active centre at positions 
K163, R415 and B: R88 and improving the enzyme structural stability at position V153. With a 
minimal number of seven mutations, we designed an enzyme that shows an outstanding reaction 
rate improvement (> 1716-fold) and yields an enantiomeric pure (S)-amine product with ee value 
of > 99%. This variant retains 90% of activity for 18h at 50°C. 
It is noteworthy that the WT enzyme does not show any detectable activity towards 2-
acetylbiphenyl. Our data showed that initial weak promiscuous activities towards a substrate are 
not always a necessity for enzyme evolution. By correctly selecting functionally relevant 
mutations, multi-step rational mutagenesis can successfully provide a more efficient pathway for 
evolution, while Nature most commonly follows smooth weak trade-off routes, hence requiring 
substantial number of sequence modifications to gain a new function (i.e. new mutations 
accumulate while maintaining the robust native activity). Our results show that amine TAm 
displays a high plasticity, enabling us to evolve it with few mutations starting from an enzyme 
with no detectable initial promiscuous activity towards a bulky ketone substrate like 2-
acetylbiphenyl.   
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